Neos Therapeutics (NASDAQ:NEOS) has entered into a confidential settlement and licensing agreement with Teva Pharmaceuticals (NYSE:TEVA) to resolve all ongoing litigation involving Neos’ patents protecting its Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets and Teva’s ANDA filed with the FDA to market a generic version of that product.
Under the settlement and license agreement, Neos has granted Teva the right to manufacture and market its generic version of Cotempla XR-ODT under the Teva ANDA beginning on July 1, 2026, or earlier.
The settlement and licensing agreement is confidential and the agreement is subject to submission to the Federal Trade Commission and the U.S. Department of Justice.
TEVA shares are up 2% premarket.
